Cargando…
Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
IMPORTANCE: Little is known about how out-of-pocket burden differs between Medicare and commercial insurance for ultra-expensive drugs. OBJECTIVE: To investigate out-of-pocket spending for ultra-expensive drugs in the Medicare Part D program vs commercial insurance. DESIGN, SETTING, AND PARTICIPANTS...
Autores principales: | DiStefano, Michael J., Kang, So-Yeon, Parasrampuria, Sonal, Anderson, Gerard F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220512/ https://www.ncbi.nlm.nih.gov/pubmed/37234016 http://dx.doi.org/10.1001/jamahealthforum.2023.1090 |
Ejemplares similares
-
Association of Out-of-Pocket Spending With Insulin Adherence in Medicare Part D
por: Trish, Erin, et al.
Publicado: (2021) -
Out-of-Pocket Spending for Influenza Hospitalizations in Medicare Advantage
por: Chua, Kao-Ping, et al.
Publicado: (2021) -
Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018
por: Alpern, Jonathan D., et al.
Publicado: (2022) -
Discussing patients’ insurance and out-of-pocket expenses during GPs’ consultations
por: Victoor, A., et al.
Publicado: (2019) -
Spending and Out-of-Pocket Prices for Brand-Name Drugs Among Commercially Insured Individuals in Massachusetts, 2015-2017
por: Aaron, Micah B., et al.
Publicado: (2021)